WO1997038674B1 - Ophthalmic compound with extended dwell time on the eye - Google Patents
Ophthalmic compound with extended dwell time on the eyeInfo
- Publication number
- WO1997038674B1 WO1997038674B1 PCT/EP1997/001138 EP9701138W WO9738674B1 WO 1997038674 B1 WO1997038674 B1 WO 1997038674B1 EP 9701138 W EP9701138 W EP 9701138W WO 9738674 B1 WO9738674 B1 WO 9738674B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preservative
- ophthalmic composition
- eye
- composition according
- ophthalmic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003755 preservative agent Substances 0.000 claims abstract 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 239000000654 additive Substances 0.000 claims abstract 3
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 239000012530 fluid Substances 0.000 claims abstract 2
- 239000002674 ointment Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 20
- 230000002335 preservative Effects 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229940012356 Eye Drops Drugs 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229940045997 Vitamin A Drugs 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000607 artificial tear Substances 0.000 claims 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzyl-dodecyl-dimethylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 claims 1
- 229940096529 carboxypolymethylene Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 229920001206 natural gum Polymers 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 229920001888 polyacrylic acid Polymers 0.000 claims 1
- 230000002035 prolonged Effects 0.000 claims 1
- 229960003471 retinol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Abstract
An ophthalmic compound with an extended dwell time on the eye, especially in the form of a drip gel, a salve or the like, containing a fluid base of increased viscosity and a preserving agent and possibly one or more active agents and common additives, like isotoning agents, substances for adjusting the pH, etc. According to the invention, the preserving agent consists essentially of a benzyl lauryl dimethyl ammonium salt. The invention also relates to the use of a benzyl lauryl dimethyl ammonium salt as a preserving agent in the production of ophthalmic compounds intended for repeated use over long periods and/or formulated for extended dwell time on the eye after each application, by means of which irritations of and/or tissue damage to the eye are prevented.
Claims
1. Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge, in Form eines tropfbaren Gels, enthaltend einen fließfähigen Träger mit erhöhter Viskosität und ein Konservierungsmittel, sowie gegebenenfalls einen oder mehrere Wirkstoffe und übliche Zusätze, wie Isotonisierungsmittel, Substanzen zur Einstellung des pH-Wertes, etc., dadurch gekennzeichnet, daß das Konservierungsmittel im wesentlichen von einem Benzyllauryldimethylammonium-Salz gebildet wird.An ophthalmic composition having an extended residence time on the eye, in the form of a drippable gel, containing a flowable carrier with increased viscosity and a preservative, and optionally one or more active ingredients and conventional additives, such as isotonizing agents, substances for adjusting the pH, etc. , characterized in that the preservative is essentially formed by a benzyllauryldimethylammonium salt.
2. Ophthalmische Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß die Zusammensetzung als Träger eine wäßrige, tropfbare Gelbasis aufweist.2. An ophthalmic composition according to claim 1, characterized in that the composition comprises as a carrier an aqueous, drippable gelatin.
3. Ophthalmische Zusammensetzung nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß der Träger der Zusammensetzung wenigstens ein Viskositätserhöhendes synthetisches oder natürliches Polymer in wäßriger Lösung oder Dispersion enthält.3. Ophthalmic composition according to claim 1 or 2, characterized in that the carrier of the composition contains at least one viscosity-increasing synthetic or natural polymer in aqueous solution or dispersion.
4. Ophthalmische Zusammensetzung nach Anspruch 3, dadurch gekennzeichnet, daß das Polymer ein Carboxyvinyl- polymer, insbesondere ein Carboxypolymethylen, oder ein Ethylen-Maleinanhydrid-Copolymer umfaßt. - 14 -4. Ophthalmic composition according to claim 3, characterized in that the polymer comprises a carboxyvinyl polymer, in particular a carboxypolymethylene, or an ethylene-maleic anhydride copolymer. - 14 -
5. Ophthalmische Zusammensetzung nach Anspruch 3, dadurch gekennzeichnet, daß das Polymer ein Cellulosede- rivat, ein natürliches Gummi wie Xanthan, ein Dextrande- rivat oder dergleichen umfaßt.5. An ophthalmic composition according to claim 3, characterized in that the polymer comprises a cellulose derivative, a natural gum such as xanthan gum, a dextran derivative or the like.
6. Ophthalmische Zusammensetzung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der flüssige Anteil der Zusam¬ mensetzung als einphasige wäßrige Flüssigkeit vorliegt.6. Ophthalmic composition according to one of claims 1 to 5, characterized in that the liquid fraction of the composition is in the form of a single-phase aqueous liquid.
7. Ophthalmische Zusammensetzung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet:, daß der flüssige Anteil der Zusam¬ mensetzung als zweiphasige Flüssigkeit, vorzugsweise als O/W-Emulsion vorliegt.7. Ophthalmic composition according to one of claims 1 to 5, characterized in that the liquid fraction of the composition is in the form of a two-phase liquid, preferably an O / W emulsion.
8. Ophthalmische Zusammensetzung nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß das Konservierungsmittel Benzyllauryldimethylammoniumchlorid ist.8. Ophthalmic composition according to one of claims 1 to 7, characterized in that the preservative is benzyllauryldimethylammonium chloride.
9. Ophthalmische Zusammensetzung nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, daß die Konzentration des Konser- vierungsmittels, bezogen auf die Gesamtmenge der Zusam¬ mensetzung, zwischen 0,001 Gew.-% und 0,5 Gew.-%, vorzugs¬ weise zwischen 0,01 Gew.-% und 0,05 Gew.-% liegt.9. Ophthalmic composition according to one of claims 1 to 8, characterized in that the concentration of the preservative, based on the total amount of Zusam¬ composition, between 0.001 wt .-% and 0.5 wt .-%, preferably wise between 0.01 wt .-% and 0.05 wt .-% is.
10. Ophthalmische Zusammensetzung nach einem der An- Sprüche 1 bis 9, dadurch gekennzeichnet, daß die Zusammensetzung als Wirkstoff Vitamin A enthält.10. An ophthalmic composition according to any one of arrival claims 1 to 9, characterized in that the composition contains as active ingredient vitamin A.
11. Ophthalmische Zusammensetzung nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, daß die Zusammensetzung 0,001 bis 1 Gew.-%, vorzugsweise 0,1 bis 0,5 Gew.-% Carboxypoly- - 1 5 -11. An ophthalmic composition according to any one of claims 1 to 10, characterized in that the composition 0.001 to 1 wt .-%, preferably 0.1 to 0.5 wt .-% Carboxypoly- - 1 5 -
ethylen, 0,0005 bis 0,05 Gew.-%, bevorzugt 0,001 bis 0,01 Gew.-% Benzyllauryldimethylammoniumchlorid, 0,1 bis 10 Gew.-%, bevorzugt 1 bis 5 Gew.-% Sorbitol, sowie Alkali¬ hydroxid bzw. Säure zur Einstellung eines physiologisch akzeptablen pH-Wertes und im übrigen Wasser umfaßt.ethylene, 0.0005 to 0.05 wt .-%, preferably 0.001 to 0.01 wt .-% Benzyllauryldimethylammoniumchlorid, 0.1 to 10 wt .-%, preferably 1 to 5 wt .-% sorbitol, and Alkali¬ hydroxide or acid to adjust a physiologically acceptable pH and the rest water.
12. Verwendung eines Benzyllauryldimethylammonium- Salzes als Konservierungsmittel zur Herstellung ophthal- mischer Zusammensetzungen, die zur wiederholten Anwendung über längere Zeiträume bestimmt sind und/oder für eine längere Verweildauer am Auge nach jeder Anwendung formu¬ liert sind, wodurch Irritationen und/oder Gewebeschädi¬ gungen des Auges vermieden werden.12. Use of a Benzyllauryldimethylammonium- salt as a preservative for the preparation of ophthalmic compositions which are intended for repeated use over long periods and / or formulated for a longer residence time on the eye after each application liert, causing irritation and / or Gewebeschädi¬ tions of the eye to be avoided.
13. Verwendung von Benzyllauryldimethylammoniumchlorid gemäß Anspruch 12.13. Use of Benzyllauryldimethylammoniumchlorid according to claim 12.
14. Verwendung des Konservierungsmittels gemäß Anspruch 12 oder 13 für mit wenigstens einem Wirkstoff versehene Augentropfen.14. Use of the preservative according to claim 12 or 13 for provided with at least one active ingredient eye drops.
15. Verwendung des Konservierungsmittels gemäß Anspruch 12 oder 13 für eine künstliche Tränenflüssigkeit.15. Use of the preservative according to claim 12 or 13 for an artificial tear fluid.
16. Verwendung einer ophthalmisehen Zusammensetzung zur verlängerten Verweilzeit am Auge, nach einem der Ansprüche 2 bis 11, insbesondere in Form eines tropfbaren Gels, einer Salbe oder dergleichen, enthaltend einen fließfähigen Träger mit erhöhter Viskosität und ein Konservierungsmittel, sowie gegebenenfalls einen oder mehrere Wirkstoffe und übliche Zusätze, wie Iso- tonisierungsmittel, Substanzen zur Einstellung des pH- Wertes, etc., wobei das Konservierungsmittel im wesentlichen von einem Benzyllauryldimethylammonium-Salz gebildet wird. 16. Use of an ophthalmic composition for prolonged retention on the eye, according to any one of claims 2 to 11, in particular in the form of a drippable gel, an ointment or the like, comprising a flowable carrier with increased viscosity and a preservative, and optionally one or more active ingredients and customary additives, such as isotonicizing agents, substances for adjusting the pH, etc., the preservative being essentially formed by a benzyl lauryldimethylammonium salt.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU20246/97A AU714093B2 (en) | 1996-04-15 | 1997-03-06 | Ophthalmic composition with prolonged residence time on the eye |
| US09/171,344 US6599944B1 (en) | 1996-04-15 | 1997-03-06 | Ophtalmic compound with extended dwell time on the eye |
| PL97328656A PL187339B1 (en) | 1996-04-15 | 1997-03-06 | Ophthalmic composition of extended time of their retention in eyes |
| JP53667697A JP4582822B2 (en) | 1996-04-15 | 1997-03-06 | Eye drop composition with a long residence time in the eye |
| CA002251982A CA2251982C (en) | 1996-04-15 | 1997-03-06 | Ophthalmic compound with extended dwell time on the eye |
| BR9708669A BR9708669A (en) | 1996-04-15 | 1997-03-06 | Ophthalmic composition with prolonged residence time in the eye |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19614823.5 | 1996-04-15 | ||
| DE19614823A DE19614823A1 (en) | 1996-04-15 | 1996-04-15 | Ophthalmic composition with prolonged retention time on the eye |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/171,344 A-371-Of-International US6599944B1 (en) | 1996-04-15 | 1997-03-06 | Ophtalmic compound with extended dwell time on the eye |
| US10/625,634 Continuation US20040071778A1 (en) | 1996-04-15 | 2003-07-23 | Ophthalmic compound with extended dwell time on the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997038674A1 WO1997038674A1 (en) | 1997-10-23 |
| WO1997038674B1 true WO1997038674B1 (en) | 1997-11-20 |
Family
ID=7791310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/001138 WO1997038674A1 (en) | 1996-04-15 | 1997-03-06 | Ophthalmic compound with extended dwell time on the eye |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6599944B1 (en) |
| EP (1) | EP0801948B1 (en) |
| JP (1) | JP4582822B2 (en) |
| CN (1) | CN1215988A (en) |
| AT (1) | ATE201820T1 (en) |
| AU (1) | AU714093B2 (en) |
| BR (1) | BR9708669A (en) |
| CA (1) | CA2251982C (en) |
| DE (2) | DE19614823A1 (en) |
| DK (1) | DK0801948T3 (en) |
| ES (1) | ES2159783T3 (en) |
| GR (1) | GR3036498T3 (en) |
| PL (1) | PL187339B1 (en) |
| PT (1) | PT801948E (en) |
| SI (1) | SI0801948T1 (en) |
| WO (1) | WO1997038674A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19614823A1 (en) | 1996-04-15 | 1997-10-16 | Mann Gerhard Chem Pharm Fab | Ophthalmic composition with prolonged retention time on the eye |
| DE19744113A1 (en) * | 1997-10-06 | 1999-04-15 | Mann Gerhard Chem Pharm Fab | Ophthalmological dexamethasone preparation |
| IN185228B (en) * | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
| DE19918324A1 (en) * | 1999-04-22 | 2000-10-26 | Mann Gerhard Chem Pharm Fab | Bactericidal, virucidal, fungicidal and antiprotozoal pharmaceutical composition, especially for ophthalmological use, contains benzalkonium salt |
| DE19938668B4 (en) * | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Artificial tears |
| DE10132876A1 (en) * | 2001-07-06 | 2003-01-30 | Medproject Pharma Entwicklungs | Two-phase, drop-onable hydrogels for use on the eye |
| EP2227197A4 (en) * | 2007-12-05 | 2011-06-22 | Avedro Inc | Eye therapy system |
| WO2010039854A1 (en) * | 2008-09-30 | 2010-04-08 | Neal Marshall | Eye therapy system |
| WO2011050164A1 (en) | 2009-10-21 | 2011-04-28 | Avedro, Inc. | Eye therapy |
| WO2011116306A2 (en) * | 2010-03-19 | 2011-09-22 | Avedro, Inc. | Systems and methods for applying and monitoring eye therapy |
| WO2012162529A1 (en) | 2011-05-24 | 2012-11-29 | Avedro, Inc. | Systems and methods for reshaping an eye feature |
| WO2012167260A2 (en) | 2011-06-02 | 2012-12-06 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
| CN102416011A (en) * | 2011-10-10 | 2012-04-18 | 艾硕特生物科技（昆明）有限公司 | Broad-spectrum and high-efficiency antibacterial washing liquor |
| KR102154880B1 (en) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP2844295A1 (en) | 2012-05-03 | 2015-03-11 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP2872081B1 (en) | 2012-07-16 | 2022-06-08 | Avedro, Inc. | Systems for corneal cross-linking with pulsed light |
| US9498114B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US9498122B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US9308165B2 (en) * | 2013-08-22 | 2016-04-12 | Therapeutic Vision, Inc. | Composition for treating ocular effects of diabetes |
| WO2016069628A1 (en) | 2014-10-27 | 2016-05-06 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
| WO2016077747A1 (en) | 2014-11-13 | 2016-05-19 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
| WO2016172695A1 (en) | 2015-04-24 | 2016-10-27 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| EP3297589A4 (en) | 2015-05-22 | 2019-03-06 | Avedro Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
| CN116832158A (en) | 2015-07-21 | 2023-10-03 | 艾维德洛公司 | Systems and methods for treating eyes with photosensitizers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4053628A (en) * | 1971-05-12 | 1977-10-11 | Fisons Limited | Composition |
| GB1399834A (en) * | 1971-05-12 | 1975-07-02 | Fisons Ltd | Pharmaceutical compositions |
| AU499860B2 (en) * | 1975-04-24 | 1979-05-03 | Honda Giken Kogyo Kabushiki Kaisha | Deflector plate to equalise fuel distribution in induction gas flow |
| JPS5313588A (en) * | 1976-07-23 | 1978-02-07 | Alcon Lab Inc | Ophthalmic solution |
| GB2013084B (en) * | 1978-01-25 | 1982-07-28 | Alcon Lab Inc | Ophthalmic drug dosage |
| US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| DE3415663A1 (en) * | 1984-04-27 | 1985-10-31 | Sandoz-Patent-GmbH, 7850 Lörrach | Ophthalmological administration form |
| US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5032392A (en) * | 1986-09-04 | 1991-07-16 | Vision Pharmaceuticals | Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes |
| FR2665635A1 (en) * | 1990-08-10 | 1992-02-14 | Merck Sharp & Dohme | FLUID PHARMACEUTICAL COMPOSITION BASED ON METAL COMPLEX AND PROCESS FOR PREPARING THE SAME. |
| FR2678832B1 (en) * | 1991-07-10 | 1995-03-17 | Europhta Sa Laboratoire | NOVEL OPHTHALMIC COMPOSITIONS WITH IMPROVED RESORPTION AND METHODS OF PREPARING THE SAME. |
| FR2679773A1 (en) * | 1991-07-30 | 1993-02-05 | Merck Sharp & Dohme | Ophthalmic preparation containing an acceptable antimicrobial osmotic agent |
| AU5599594A (en) * | 1992-11-16 | 1994-06-08 | Ciba-Geigy Ag | Polyvinyl alcohol/borate ophthalmic drug delivery system |
| AU6021794A (en) * | 1993-01-11 | 1994-08-15 | Allergan, Inc. | Ophthalmic compositions comprising benzyllauryldimethylammonium chloride |
| DE19614823A1 (en) | 1996-04-15 | 1997-10-16 | Mann Gerhard Chem Pharm Fab | Ophthalmic composition with prolonged retention time on the eye |
-
1996
- 1996-04-15 DE DE19614823A patent/DE19614823A1/en not_active Withdrawn
-
1997
- 1997-03-06 BR BR9708669A patent/BR9708669A/en not_active IP Right Cessation
- 1997-03-06 EP EP97103736A patent/EP0801948B1/en not_active Expired - Lifetime
- 1997-03-06 CA CA002251982A patent/CA2251982C/en not_active Expired - Lifetime
- 1997-03-06 CN CN97193787A patent/CN1215988A/en active Pending
- 1997-03-06 SI SI9730178T patent/SI0801948T1/en unknown
- 1997-03-06 DE DE59703711T patent/DE59703711D1/en not_active Expired - Lifetime
- 1997-03-06 AU AU20246/97A patent/AU714093B2/en not_active Ceased
- 1997-03-06 JP JP53667697A patent/JP4582822B2/en not_active Expired - Lifetime
- 1997-03-06 AT AT97103736T patent/ATE201820T1/en active
- 1997-03-06 US US09/171,344 patent/US6599944B1/en not_active Expired - Lifetime
- 1997-03-06 PL PL97328656A patent/PL187339B1/en unknown
- 1997-03-06 WO PCT/EP1997/001138 patent/WO1997038674A1/en active Application Filing
- 1997-03-06 ES ES97103736T patent/ES2159783T3/en not_active Expired - Lifetime
- 1997-03-06 PT PT97103736T patent/PT801948E/en unknown
- 1997-03-06 DK DK97103736T patent/DK0801948T3/en active
-
2001
- 2001-08-31 GR GR20010401358T patent/GR3036498T3/en unknown
-
2003
- 2003-07-23 US US10/625,634 patent/US20040071778A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997038674B1 (en) | Ophthalmic compound with extended dwell time on the eye | |
| EP0340592B2 (en) | Hair treatment composition with natural ingredients | |
| DE69228943T2 (en) | AGENT AND SKIN TREATMENT METHOD FOR REDUCING ACNE AND MASCULAR HAIR LOSS | |
| DE68913239T2 (en) | Preservative composition for wet wipers. | |
| EP0801948B1 (en) | Ophthalmic composition having prolonged residence time in the eye | |
| DE3012767C2 (en) | ||
| DE69800170T2 (en) | System consisting of phosphonic acid derivatives and metabisulphite to stabilize ascorbic acid | |
| DE69717101T2 (en) | USE OF ALKYL GLUCOSIDES AND THEIR ESTERS AS ANTIMICROBIAL EMULSIFIERS | |
| CH627645A5 (en) | Cosmetic composition for smoothing the skin | |
| US5654341A (en) | Low pH skin-treatment composition | |
| DE69403025T2 (en) | Cosmetic or dermatological preparation in the form of a stable oil-in-water emulsion which contains at least one vegetable oil which consists of at least 40% linoleic acid triglyceride | |
| DE102005058978A1 (en) | Wound and mucous membrane disinfectant | |
| WO1990004382A1 (en) | Preserved hair and body care products and the use of a combined preservative | |
| DE60303735T2 (en) | Liquid concentrate for the preservation of cosmetic and pharmaceutical products | |
| DE69900160T2 (en) | Composition containing urea and its uses in cosmetics and / or dermatology | |
| DE69402826T2 (en) | COMPOSITION FOR HAIR CARE | |
| EP0120224B1 (en) | Functional oil cream bath | |
| EP2056781B1 (en) | Anhydrous dermatological or cosmetic preparation comprising urea | |
| DE3784821T2 (en) | COMPOSITION FOR USE ON HAIR. | |
| DE60106014T2 (en) | USE OF N, N'-DIBENZYLETHYLENEDIAMINO-SODIUM DERIVATIVES FOR PROTECTION AGAINST POLLUTION | |
| DE68907755T2 (en) | Anti-graying agent and repigmentation of graying hair. | |
| DE68906194T2 (en) | Preparation for external use on the skin. | |
| EP0625041B1 (en) | Aqueous cleaning products | |
| DE69321540T2 (en) | Corn eye containing NaOH | |
| DE10020874A1 (en) | Cosmetic preparation useful for reduction of skin wrinkles, comprises Dead Sea salt and coenzyme Q10 |